company background image
6696

Lin BioScience TPEX:6696 Stock Report

Last Price

NT$176.50

Market Cap

NT$12.7b

7D

-12.8%

1Y

-25.7%

Updated

15 May, 2022

Data

Company Financials
6696 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6696 Stock Overview

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.

Lin BioScience Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Lin BioScience
Historical stock prices
Current Share PriceNT$176.50
52 Week HighNT$271.50
52 Week LowNT$123.50
Beta-0.14
1 Month Change-30.78%
3 Month Change-19.41%
1 Year Change-25.68%
3 Year Change364.47%
5 Year Changen/a
Change since IPO260.13%

Recent News & Updates

Mar 24
We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, Lin BioScience...

Dec 10
We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

6696TW BiotechsTW Market
7D-12.8%-5.1%-3.4%
1Y-25.7%9.1%0.7%

Return vs Industry: 6696 underperformed the TW Biotechs industry which returned 9.1% over the past year.

Return vs Market: 6696 underperformed the TW Market which returned 0.7% over the past year.

Price Volatility

Is 6696's price volatile compared to industry and market?
6696 volatility
6696 Average Weekly Movement9.1%
Biotechs Industry Average Movement5.3%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.3%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6696 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 6696's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aTom Linhttps://www.linbioscience.com

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (AMD) and stargardt diseases; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei City, Taiwan.

Lin BioScience Fundamentals Summary

How do Lin BioScience's earnings and revenue compare to its market cap?
6696 fundamental statistics
Market CapNT$12.74b
Earnings (TTM)-NT$434.70m
Revenue (TTM)n/a

0.0x

P/S Ratio

-29.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6696 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$434.70m
Earnings-NT$434.70m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-6.02
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6696 perform over the long term?

See historical performance and comparison

Valuation

Is Lin BioScience undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


23.52x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6696's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6696's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: 6696 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6696 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6696's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6696 is overvalued based on its PB Ratio (23.5x) compared to the TW Biotechs industry average (3.8x).


Future Growth

How is Lin BioScience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


125.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lin BioScience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Lin BioScience performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6696 is currently unprofitable.

Growing Profit Margin: 6696 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6696 is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.

Accelerating Growth: Unable to compare 6696's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6696 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).


Return on Equity

High ROE: 6696 has a negative Return on Equity (-106.17%), as it is currently unprofitable.


Financial Health

How is Lin BioScience's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6696's short term assets (NT$819.5M) exceed its short term liabilities (NT$470.3M).

Long Term Liabilities: 6696 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 6696 is debt free.

Reducing Debt: 6696 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6696 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6696 has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 7.7% each year.


Dividend

What is Lin BioScience current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6696's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6696's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6696's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6696's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6696 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Tom Lin

no data

Tenure

Dr. Yuxin Lin, also known as Tom, MBA MMed PhD(Med), serves as Chairman and Chief Executive Officer of Lin BioScience, Inc. Prior to founding Lin Bioscience, Dr. Lin has served as President, Chief Operatio...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.


Top Shareholders

Company Information

Lin BioScience, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lin BioScience, Inc.
  • Ticker: 6696
  • Exchange: TPEX
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: NT$12.739b
  • Shares outstanding: 72.17m
  • Website: https://www.linbioscience.com

Location

  • Lin BioScience, Inc.
  • No. 68, Zhongxiao East Road
  • 12th Floor, Section 5
  • Taipei
  • 110
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.